Abstract:Hengfeng Liao 1, 2 , Yue Gao 1, 2 , Chunfang Lian 1, 2 , Yun Zhang 1, 2 , Bangyuan Wang 1, 2 , Yanfang Yang 1, 2 , Jun Ye 1, 2 , Yu Feng 1, 2 , Yuling Liu 1, 2 1 State Key Laboratory of Bioactive substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China; 2 Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, People's Republic of China Correspondence: Yuling Liu State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 1 Xiannongtan Street, Beijing 100050, People's Republic of China Tel +86 108 928 5188 Fax +86 108 928 5190 Email ylliu@imm.ac.cn Purpose: The aims of this study were to prepare a baicalein self-microemulsion with baicalein-phospholipid complex as the intermediate (BAPC-SMEDDS) and to compare its effects with those of conventional baicalein self-microemulsion (CBA-SMEDDS) on baicalein oral absorption and lymphatic transport. Methods: Two SMEDDS were characterized by emulsifying efficiency, droplet size, zeta potential, cloud point, dilution stability, physical stability, and in vitro release and lipolysis. Different formulations of 40 mg/kg baicalein were orally administered to Sprague-Dawley rats to investigate their respective bioavailabilities. The chylomicron flow blocking rat model was used to evaluate their lymphatic transport. Results: The droplet sizes of BAPC-SMEDDS and CBA-SMEDDS after 100x dilution were 9.6±0.2 nm and 11.3±0.4 nm, respectively. In vivo experiments indicated that the relative bioavailability of CBA-SMEDDS and BAPC-SMEDDS was 342.5% and 448.7% compared to that of free baicalein (BA). The AUC 0–t and C max of BAPC-SMEDDS were 1.31 and 1.87 times higher than those of CBA-SMEDDS, respectively. The lymphatic transport study revealed that 81.2% of orally absorbed BA entered the circulation directly through the portal vein, whereas approximately 18.8% was transported into the blood via lymphatic transport. CBA-SMEDDS and BAPC-SMEDDS increased the lymphatic transport ratio of BA from 18.8% to 56.2% and 70.2%, respectively. Therefore, self-microemulsion not only significantly improves oral bioavailability of baicalein, but also increases the proportion lymphatically transported. This is beneficial to the direct interaction of baicalein with relevant immune cells in the lymphatic system and for proper display of its effects. Conclusion: This study demonstrates the oral absorption and lymphatic transport characteristics of free baicalein and baicalein SMEDDS with different compositions. This is of great significance to studies on lymphatic targeted delivery of natural immunomodulatory compounds. Keywords: SMEDDS, phospholipid complex, baicalein, oral bioavailability, lymphatic transport

In Vitroandin Vivostudy of Baicalin-loaded Mixed Micelles for Oral Delivery

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion

In Vitro Characterization and in Vivo Evaluation of Nanostructured Lipid Curcumin Carriers for Intragastric Administration

Preparation, characterisation and in vitro anti-inflammatory activity of Baicalin microsponges

Baicalin-berberine complex nanocrystals orally promote the co-absorption of two components

Enhancing the Oral Bioavailability of Biochanin A by Encapsulation in Mixed Micelles Containing Pluronic F127 and Plasdone S630

Nanostructured Lipid Carriers As a Delivery System of Biochanin A

Baicalin loaded in folate-PEG modified liposomes for enhanced stability and tumor targeting.

Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo

Characterization and Evaluation in Vivo of Baicalin-Nanocrystals Prepared by an Ultrasonic-Homogenization-fluid Bed Drying Method

Preparation and evaluation of self-microemulsifying drug delivery system of baicalein

Preparation, Characterization and in Vivo Evaluation of Formulation of Baicalein with Hydroxypropyl-Beta-Cyclodextrin

Long-circulating nanoliposomes (LCNs) sustained delivery of baicalein (BAI) with desired oral bioavailability in vivo

Preparation, optimization, characterization and in vitro release of baicalein-solubilizing glycyrrhizic acid nano-micelles

Improved Bioavailability and Hepatoprotective Activity of Baicalein Via a Self-assembled Solutol HS15 Micelles System

Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems

Preparation of Baicalin Liposomes Using Microfluidic Technology and Evaluation of Their Antitumor Activity by a Zebrafish Model

Cationic Curcumin Nanocrystals Liposomes for Improved Oral Bioavailability: Formulation Development, Optimization, In Vitro and In Vivo Evaluation

Diammonium Glycyrrhizinate-Based Micelles for Improving the Hepatoprotective Effect of Baicalin: Characterization and Biopharmaceutical Study

Binary Pluronics based mixed micellar systems: Effective solution for improved solubilization of Biochanin A